[{"address1": "200-3650 Gilmore Way", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 316, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 48, "title": "President, CEO, Principal Accounting Officer & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1184288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 56, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 682252, "exercisedValue": 0, "unexercisedValue": 436894}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 774702, "exercisedValue": 0, "unexercisedValue": 4053263}, {"maxAge": 1, "name": "Mr. Thomas Patrick Kelly J.D.", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew D. Ronsheim Ph.D.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McClCoskey B.A.", "age": 64, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 63, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 63, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darren S. Cline M.B.A.", "age": 60, "title": "Chief Commercial Officer and Member of Executive Team", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "J.P.  Gilbert", "title": "Senior Director", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 2, "compensationRisk": 8, "shareHolderRightsRisk": 3, "overallRisk": 5, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 38.3, "open": 38.28, "dayLow": 37.23, "dayHigh": 38.405, "regularMarketPreviousClose": 38.3, "regularMarketOpen": 38.28, "regularMarketDayLow": 37.23, "regularMarketDayHigh": 38.405, "payoutRatio": 0.0, "beta": 1.034, "forwardPE": -10.744382, "volume": 453580, "regularMarketVolume": 453580, "averageVolume": 798620, "averageVolume10days": 862300, "averageDailyVolume10Day": 862300, "bid": 38.16, "ask": 38.34, "bidSize": 1, "askSize": 1, "marketCap": 2955769088, "fiftyTwoWeekLow": 26.74, "fiftyTwoWeekHigh": 45.45, "allTimeHigh": 50.99, "allTimeLow": 2.1, "priceToSalesTrailing12Months": 394.10254, "fiftyDayAverage": 39.3874, "twoHundredDayAverage": 35.703526, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2501827840, "profitMargins": 0.0, "floatShares": 71764524, "sharesOutstanding": 77275005, "sharesShort": 6148669, "sharesShortPriorMonth": 7040555, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0797, "heldPercentInsiders": 0.0014300001, "heldPercentInstitutions": 1.10846, "shortRatio": 7.91, "shortPercentOfFloat": 0.0889, "impliedSharesOutstanding": 77275005, "bookValue": 7.255, "priceToBook": 5.272226, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -306334016, "trailingEps": -3.89, "forwardEps": -3.56, "enterpriseToRevenue": 333.577, "enterpriseToEbitda": -7.398, "52WeekChange": -0.13206261, "SandP52WeekChange": 0.12121439, "quoteType": "EQUITY", "currentPrice": 38.25, "targetHighPrice": 65.0, "targetLowPrice": 43.0, "targetMeanPrice": 55.18789, "targetMedianPrice": 55.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 462268000, "totalCashPerShare": 5.982, "ebitda": -338182016, "totalDebt": 8327000, "quickRatio": 12.08, "currentRatio": 12.525, "totalRevenue": 7500000, "debtToEquity": 1.488, "revenuePerShare": 0.095, "returnOnAssets": -0.29505, "returnOnEquity": -0.45138, "grossProfits": -265211008, "freeCashflow": -162175504, "operatingCashflow": -252022000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -45.43733, "financialCurrency": "USD", "symbol": "XENE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Xenon Pharmaceuticals Inc.", "corporateActions": [], "postMarketTime": 1762551633, "regularMarketTime": 1762549201, "exchange": "NGM", "messageBoardId": "finmb_565718", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "shortName": "Xenon Pharmaceuticals Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1415197800000, "postMarketChangePercent": 0.0, "postMarketPrice": 38.25, "postMarketChange": 0.0, "regularMarketChange": -0.0499992, "regularMarketDayRange": "37.23 - 38.405", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 798620, "fiftyTwoWeekLowChange": 11.51, "fiftyTwoWeekLowChangePercent": 0.4304413, "fiftyTwoWeekRange": "26.74 - 45.45", "fiftyTwoWeekHighChange": -7.200001, "fiftyTwoWeekHighChangePercent": -0.15841585, "fiftyTwoWeekChangePercent": -13.206262, "regularMarketChangePercent": -0.130546, "regularMarketPrice": 38.25, "earningsTimestamp": 1762203600, "earningsTimestampStart": 1762203600, "earningsTimestampEnd": 1762203600, "earningsCallTimestampStart": 1762205400, "earningsCallTimestampEnd": 1762205400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.89, "epsForward": -3.56, "epsCurrentYear": -4.25572, "priceEpsCurrentYear": -8.987903, "fiftyDayAverageChange": -1.1374016, "fiftyDayAverageChangePercent": -0.028877294, "twoHundredDayAverageChange": 2.5464745, "twoHundredDayAverageChangePercent": 0.07132278, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "displayName": "Xenon Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]